Redcare Pharmacy's Prescription-Led Rally Tests Investor Conviction

Redcare Pharmacy's Q1 2026 revenue jumps 18.3%, driven by 55% growth in German e-prescriptions. The stock rebound faces profitability test amid heavy investment.

A powerful rebound in Redcare Pharmacy's share price, fueled by explosive growth in its core prescription business, is forcing the market to weigh rapid expansion against persistent profitability concerns. The stock surged approximately 26% last week, closing at EUR 50.60 and reclaiming its 50-day moving average after a brutal sell-off that saw it hit a 52-week low of EUR 31 in March.

The catalyst was a robust preliminary first-quarter report for 2026. Group revenue climbed 18.3% to EUR 848 million, already exceeding the company's full-year growth target of 13-15%. The engine of this growth is Germany's booming electronic prescription, or E-Rezept, system. Revenue from prescription medications in the country jumped 55% to EUR 168 million, securing Redcare further market share in an online segment where it already commands a 67% stake.

This operational strength is translating into a broader customer base, which expanded by one million year-over-year to 14.2 million active users. The over-the-counter (OTC) segment, which had previously lagged, also showed renewed vigor with 10% growth in Germany.

Despite the recent rally, the stock remains deeply wounded on a longer timeline, still down roughly 60% from its yearly high above EUR 136. Technical indicators underscore the extremity of the recent moves; the Relative Strength Index (RSI) sits at a deeply oversold level of 24, suggesting last week's surge was partly a technical correction.

Management is holding firm to its 2026 outlook, targeting German prescription revenues of more than EUR 670 million for the full year. The adjusted EBITDA margin is expected to reach at least 2.5%, aided by declining marketing costs relative to sales and increased automation in logistics. However, significant capital expenditures continue to pressure profitability. The company is constructing a new logistics center in Pilsen, Czech Republic, which will add annual capacity for 15 million packages. These investments have prompted a revision of the medium-term margin target from over 8% to more than 5%.

A potential political tailwind could further accelerate the prescription business. An expert commission has recommended raising the statutory co-payment for prescriptions to a range of EUR 7.50 to EUR 15, which may drive price-sensitive patients toward more affordable online alternatives like Redcare.

The company's recent Annual General Meeting on April 15 saw shareholders approve all agenda items. Anja Hendel, Max Müller, and Peter Schmid von Linstow were newly elected to the Supervisory Board, with von Linstow also taking the role of Deputy Chairman.

All eyes are now on the full quarterly report due May 6. The focus will shift from pure top-line growth to the concrete profitability metrics. The key question for investors is whether the operational margin can withstand the current high investment cycle. If it holds, last week's breakout could mark the beginning of a more sustained recovery.